ClinicalTrials.gg
CompletedNCT01791491Updated Jul 24, 2017Results posted

Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

A Phase 2 interventional study of Belatacept in Kidney Transplant, sponsored by Bristol-Myers Squibb. Completed at 8 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-07-24.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.

02

Conditions studied

  • Kidney Transplant
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Male and Female subjects,12-17 years old
  • Receiving CNI-based maintenance since the time of renal transplantation in accordance with local standard of care
  • Stable renal function, in the opinion of the investigator, with a cGFR>45 mL/min/1.73m2 at the time of enrollment (per updated Schwartz Formula)
  • Adolescent Recipients of a renal allograft from a living donor or a deceased donor at least 6 months prior to enrollment
  • Subject must be receiving a calcineurin inhibitor (CNI)-based [cyclosporine (CsA) [any formulation] or Tacrolimus (TAC)] immunosuppressive regimen
  • Subject must be receiving adjunctive background maintenance immunosuppression with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS)/mycophenolic acid (MPA)
  • Subjects may be receiving maintenance in accordance with the local standard of care
  • Negative Interferon Gamma Release Assay (IGRA) such as QuantiFERON-TB Gold test or T-Spot-TB
  • FOCBP must have negative serum or urine pregnancy test within 24 hrs prior to start of study medication
  • Subject must have stable estimated (GFR) ≥45 mL/min/1.73m2 (updated Schwartz formula)

Exclusion criteria

Exclusion Criteria:

  • Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and screening
  • History of any treated or proven acute rejection (BPAR) within 3 months prior to enrollment
  • Subjects who have experienced more than 1 episode of acute rejection (AR) of the current allograft or any antibody-mediated AR
  • Subjects with any active infection [including, but not limited to, positive cytomegalovirus (CMV) or BK viral (BKV) loads, BKV associated nephropathy (BKVAN), CMV retinitis, CMV colitis, etc.]
  • Urine albumin:creatinine ratio > 56.5 mg/mmol (> 0.5 mg albumin / mg creatinine) on a random voided urine specimen
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Belatacept

    Drug: Belatacept

Interventions

  • Single intravenous infusion of belatacept, 7.5 mg/kg

    Also known as: BMS-224818

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Belatacept

    Cmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Cmax was measured in micrograms per milliliter.

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

  2. Time of Maximum Observed Plasma Concentration (Tmax) of Belatacept

    Tmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Tmax was measured in hours (h).

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

  3. Half-Life of Elimination (T-Half) of Belatacept

    T-HALF was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). T-HALF was measured in hours (h).

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

  4. Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC (0-T)) and Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Belatacept

    AUC (0 - T) and AUC (0 - INF) were derived from serum concentration versus time data and measured in microgram hours per milliliter (µg\*h/mL). Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

  5. Total Body Clearance (CLT) of Belatacept

    CLT was the volume of abatacept cleared by the system, normalized by baseline body weight. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). CLT was measured in milliliters per hours per kilogram of body weight (mL/h/kg).

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

  6. Volume of Distribution at Steady-state (Vss) of Belatacept

    Vss was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Vss was measured in liters per kg body weight (L/kg).

    Time frame: Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57

Secondary outcomes

  1. Number of Participants With Death, Serious Adverse Events (SAEs), and Treatment-related Adverse Event (AE)

    Death was a fatal event leading to permanent cessations of all vital functions of the body. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Date of First Dose to 24 weeks post the last dose; approximately 26 weeks

  2. Number of Participants With Positive Belatacept-induced Immunogenicity Response

    Serum samples were analyzed for anti-belatacept antibodies using a validated homogenous bridging assay. The assay followed a tiered approach consistent with health authority guidance: tier 1 for screening ADA responses, tier 2 for confirming drug specificity of the ADA-positive responses, and tier 3 for titer. A neutralizing antibody assay was used to test those samples positive to the LEA29Y portion of the molecule in tier 2 and for which drug concentrations are =\>1 μg/mL. Lack of immunogenicity was defined as the absence of a positive response.

    Time frame: Baseline/Day 1, Days 15, 29, and 57

  3. Percentage of CD86 Receptor Occupancy

    Blood samples collected following the single dose belatacept infusion were assessed for CD86 receptor occupancy (CD86 RO).

    Time frame: 0.5 hours post dose on Day 1, Day 29 and Day 57

07

Results

Posted Jun 26, 2017

Participant flow

16 participants were enrolled and 9 were treated. Reasons for non-treatment: 1 withdrew consent and 6 no longer met study criteria.

Participant flow — Overall Study
MilestoneBelatacept
Started9
Completed9
Not completed0

Outcome measures

SecondaryNumber of Participants With Death, Serious Adverse Events (SAEs), and Treatment-related Adverse Event (AE)

Death was a fatal event leading to permanent cessations of all vital functions of the body. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Date of First Dose to 24 weeks post the last dose; approximately 26 weeks
Reported as:
Number · participants
Number of Participants With Death, Serious Adverse Events (SAEs), and Treatment-related Adverse Event (AE)
participantsBelatacept
Death0
SAEs4
Treatment-related AEs0
PrimaryMaximum Observed Serum Concentration (Cmax) of Belatacept

Cmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Cmax was measured in micrograms per milliliter.

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Geometric mean · micrograms per milliliter
Maximum Observed Serum Concentration (Cmax) of Belatacept
micrograms per milliliterBelatacept
Maximum Observed Serum Concentration (Cmax) of Belatacept151 ± 20
PrimaryTime of Maximum Observed Plasma Concentration (Tmax) of Belatacept

Tmax was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Tmax was measured in hours (h).

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Median · hours
Time of Maximum Observed Plasma Concentration (Tmax) of Belatacept
hoursBelatacept
Time of Maximum Observed Plasma Concentration (Tmax) of Belatacept0.733 (0.450 to 2.05)
PrimaryHalf-Life of Elimination (T-Half) of Belatacept

T-HALF was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). T-HALF was measured in hours (h).

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Mean · hours
Half-Life of Elimination (T-Half) of Belatacept
hoursBelatacept
Half-Life of Elimination (T-Half) of Belatacept173 ± 46.8
PrimaryArea Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC (0-T)) and Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Belatacept

AUC (0 - T) and AUC (0 - INF) were derived from serum concentration versus time data and measured in microgram hours per milliliter (µg\*h/mL). Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL).

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Geometric mean · microgram hours per milliliter
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC (0-T)) and Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Belatacept
microgram hours per milliliterBelatacept
AUC (0-T)15145 ± 25
AUC(INF)15407 ± 25
PrimaryTotal Body Clearance (CLT) of Belatacept

CLT was the volume of abatacept cleared by the system, normalized by baseline body weight. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). CLT was measured in milliliters per hours per kilogram of body weight (mL/h/kg).

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Geometric mean · milliliters per hours per kilogram
Total Body Clearance (CLT) of Belatacept
milliliters per hours per kilogramBelatacept
Total Body Clearance (CLT) of Belatacept0.483 ± 27
PrimaryVolume of Distribution at Steady-state (Vss) of Belatacept

Vss was derived from serum concentration versus time data. Serum samples were analyzed for abatacept by a validated enzyme-linked immunosorbent assay (ELISA) and were obtained at: pre-dose (0 hours), 0.5 and 2 hours from Start of Infusion on Day 1, Day 29, and Day 57. The results were summarized. The lower limit of assay quantitation (LLOQ) was set to "zero" which was 0.003 micrograms per milliliter (ug/mL). Vss was measured in liters per kg body weight (L/kg).

Time frame:
Pre-dose (0), 0.5hr and 2hr from the start of infusion on Day 1, Day 29, and Day 57
Reported as:
Geometric mean · Liters per kilogram
Volume of Distribution at Steady-state (Vss) of Belatacept
Liters per kilogramBelatacept
Volume of Distribution at Steady-state (Vss) of Belatacept0.088 ± 30
SecondaryNumber of Participants With Positive Belatacept-induced Immunogenicity Response

Serum samples were analyzed for anti-belatacept antibodies using a validated homogenous bridging assay. The assay followed a tiered approach consistent with health authority guidance: tier 1 for screening ADA responses, tier 2 for confirming drug specificity of the ADA-positive responses, and tier 3 for titer. A neutralizing antibody assay was used to test those samples positive to the LEA29Y portion of the molecule in tier 2 and for which drug concentrations are =\>1 μg/mL. Lack of immunogenicity was defined as the absence of a positive response.

Time frame:
Baseline/Day 1, Days 15, 29, and 57
Reported as:
Number · participants
Number of Participants With Positive Belatacept-induced Immunogenicity Response
participantsBelatacept
Number of Participants With Positive Belatacept-induced Immunogenicity Response0
SecondaryPercentage of CD86 Receptor Occupancy

Blood samples collected following the single dose belatacept infusion were assessed for CD86 receptor occupancy (CD86 RO).

Time frame:
0.5 hours post dose on Day 1, Day 29 and Day 57
Reported as:
Mean · percent
Percentage of CD86 Receptor Occupancy
percentBelatacept
0.5 Hour94.70 ± 4.035
Day 2977.99 ± 10.983
Day 5751.45 ± 43.285

Adverse events

Collected over SAEs were reported from the date of first dose to 24 weeks post the last dose (approximately 26 weeks); AEs were reported for the on study period from the date of first dose up to 56 days post last dose (approximately 10 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belatacept—4/9 (44.4%)3/9 (33.3%)
Most frequent serious events
Most frequent serious events
EventBelatacept
GastroenteritisInfections and infestations2/9
Blood creatinine increasedInvestigations1/9
Acute kidney injuryRenal and urinary disorders1/9
PyelonephritisInfections and infestations1/9
Pyelonephritis acuteInfections and infestations1/9
Urinary tract infectionInfections and infestations1/9
Most frequent other events
Most frequent other events
EventBelatacept
HeadacheNervous system disorders2/9
Abdominal pain upperGastrointestinal disorders1/9
VomitingGastrointestinal disorders1/9
Urinary tract infectionInfections and infestations1/9
AstheniaGeneral disorders1/9
GastroenteritisInfections and infestations1/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Belatacept
Mean15.1 ± 1.17
Sex: Female, Male
Sex: Female, Male(Participants)Belatacept
Female4
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belatacept
Hispanic or Latino4
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belatacept
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White5
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
  • Childrens Hospital Of La
    Los Angeles, California 90027, United States
  • University Of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Childrens National Medical Center
    Washington, D.C., District of Columbia 20010, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Dec 2016, 42 months.

Results were first posted in Jun 2017, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2013
First posted
Feb 15, 2013
StartActual
May 9, 2013
Primary completionActual
Dec 6, 2016
CompletionActual
Dec 6, 2016
Results first posted
Jun 26, 2017
Last update
Jul 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01791491
Responsible party
Sponsor
First posted
Feb 15, 2013
Start date
May 9, 2013
Primary completion
Dec 6, 2016
Completion
Dec 6, 2016
Results posted
Jun 26, 2017
Last update
Jul 24, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion